ACS Nano · 2019 · 228 citations · 36 references
EngineeringBioengineeringBiomedical EngineeringBiosensorsMolecular DiagnosticsSensorsLiquid BiopsyMicrofluidic DevicesMicrofluidicsMicroneedle-based DeliveryNanomedicineNucleic Acid BiosensorsBiomarkersCell-free Nucleic Acid DetectionCell-free Nucleic Acid IsolationEarly DiagnosisInterstitial Fluid SensingInvasive SamplingMicroneedlesNucleic Acid Biomarkers
Minimally invasive microneedle patches can sample cell‑free nucleic acids from skin interstitial fluid, a fluid rich in biomarkers yet largely overlooked, offering a pain‑free alternative to blood for early disease diagnosis and longitudinal monitoring. The study develops alginate‑peptide nucleic acid hybrid microneedles for sequence‑specific sampling, isolation, and detection of nucleic acid biomarkers from skin interstitial fluid. The microneedles are coated with an alginate‑peptide nucleic acid hybrid hydrogel that rapidly samples ~6.5 µL in 2 min and allows light‑triggered release of captured nucleic acids for on‑patch or solution detection. The platform achieves rapid sampling of ~6.5 µL in 2 min and enables detection of specific nucleic acid biomarkers on the patch or after light‑triggered hydrogel release.
Minimally invasive technologies that can sample and detect cell-free nucleic acid biomarkers from liquid biopsies have recently emerged as clinically useful for early diagnosis of a broad range of pathologies, including cancer. Although blood has so far been the most commonly interrogated bodily fluid, skin interstitial fluid has been mostly overlooked despite containing the same broad variety of molecular biomarkers originating from cells and surrounding blood capillaries. Emerging technologies to sample this fluid in a pain-free and minimally-invasive manner often take the form of microneedle patches. Herein, we developed microneedles that are coated with an alginate-peptide nucleic acid hybrid material for sequence-specific sampling, isolation, and detection of nucleic acid biomarkers from skin interstitial fluid. Characterized by fast sampling kinetics and large sampling capacity (∼6.5 μL in 2 min), this platform technology also enables the detection of specific nucleic acid biomarkers either on the patch itself or in solution after light-triggered release from the hydrogel. Considering the emergence of cell-free nucleic acids in bodily fluids as clinically informative biomarkers, platform technologies that can detect them in an automated and minimally invasive fashion have great potential for personalized diagnosis and longitudinal monitoring of patient-specific disease progression.
36
The functions of animal microRNAs
Victor Ambros · Nature · 2004 · 10.8K citations
MicroRNA expression profiles classify human cancers
Jun Lü, Gad Getz, Eric A. Miska et al. · Nature · 2005 · 9.6K citations
Xi Chen, Yi Ba, Lijia Ma et al. · Cell Research · 2008 · 4.6K citations
The MicroRNA Spectrum in 12 Body Fluids
Jessica A. Weber, David Baxter, Shile Zhang et al. · Clinical Chemistry · 2010 · 2.7K citations · Full text
PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules
Ole Buchardt, Leif Christensen, Carsten Behrens et al. · Nature · 1993 · 2.1K citations